logo
  

Vodafone Q1 Group Revenue Up 5.7%

Vodafone Group Plc. (VOD.L,VOD) reported that group revenue for the first-quarter of fiscal year 2022 increased 5.7% year-over-year to 11.10 billion euros, supported by service revenue growth in Europe and Africa, and a recovery in handset sales following COVID-19 disruption in the prior year. On an organic basis, quarterly revenue growth was 5.6%.

On an organic basis, Group service revenue growth of 3.3%, with growth across Consumer and Business segments.

Roaming and visitor revenue grew 56% year-on-year, but still 54% lower than the first-quarter of fiscal year 2020.

Europe mobile contract churn 1.6 percentage points lower than the first-quarter of fiscal year 2020 (pre-pandemic), but commercial activity yet to return to normal conditions.

The company said it is on track to deliver fiscal year 2022 guidance with Adjusted EBITDAaL expected to be between 15.0 billion euros - 15.4 billion euros and Adjusted free cash flow of at least 5.2 billion euros.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT